This application is a competing continuation of R01DE12872-05 entitled, """"""""Low-Dose Doxycycline Effects on Osteopenic Bone Loss."""""""" For the currently-funded grant, 128 postmenopausal (PM) osteopenic women with chronic periodontitis were randomized to receive either subantimicrobial dose (low-dose; LDD) doxycycline or a placebo control in a two-year randomized clinical trial. This trial is ongoing and is testing the hypothesis that LDD will reduce bone loss in the periodontium and skeletal tissues (femoral neck and lumber spine). In addition to bone loss, cardiovascular disease (CVD) is an additional clinical sequelae of menopause and recent evidence suggests that systemic inflammation plays an important role in CVD pathogenesis. Importantly, we recently demonstrated that LDD reduces biomarkers of systemic inflammation in acute coronary syndromes patients. The NIDCR and Data and Safety Monitoring Board approved an addendum consent form subsequent to our March 2004 meeting; these signed consent forms give us permission to examine serum inflammatory biomarkers in response to LDD. However, no funds are available to conduct these additional assays; hence, we are applying for this competing continuation. Serum is currently being collected in our clinical trial at baseline, one-year and two-year visits and serum biomarkers of bone resorption/formation are being measured. The hypothesis for this application is that LDD can reduce biomarkers of systemic inflammation and MMPs associated with CVD risk in PM women. This hypothesis will be tested by pursuing the following specific aim: determine whether LDD therapy, in PM osteopenic women with chronic periodontitis, beneficially alters serum biomarkers of systemic inflammation and CVD (C-reactive protein, IL-6, myeloperoxidase, MMP-2 and MMP-9) in patients already enrolled in our current clinical trial. No additional serum will need to be collected for this study which will enable us to expand the significance of our currently-funded R01. This work is significant because, if LDD ultimately is found to reduce the severity of two major complications of menopause (namely, osteoporosis and increased incidence of CVD), LDD could provide an alternative to hormone replacement therapy in PM women. This work is relevant to public health as LDD may provide a safe and effective therapy to reduce complications associated with menopause. Reduced bone loss and CVD incidence would represent significant public health improvements. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
2R01DE012872-06
Application #
7090225
Study Section
Special Emphasis Panel (ZDE1-LK (13))
Program Officer
Atkinson, Jane C
Project Start
2001-07-01
Project End
2007-12-31
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
6
Fiscal Year
2006
Total Cost
$192,879
Indirect Cost
Name
University of Nebraska Medical Center
Department
Surgery
Type
Schools of Dentistry
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Bright, R; Thiele, G M; Manavis, J et al. (2018) Gingival tissue, an extrasynovial source of malondialdehyde-acetaldehyde adducts, citrullinated and carbamylated proteins. J Periodontal Res 53:139-143
Schwenzer, Anja; Quirke, Anne-Marie; Marzeda, Anna M et al. (2017) Association of Distinct Fine Specificities of Anti-Citrullinated Peptide Antibodies With Elevated Immune Responses to Prevotella intermedia in a Subgroup of Patients With Rheumatoid Arthritis and Periodontitis. Arthritis Rheumatol 69:2303-2313
Payne, Jeffrey B; Nummikoski, Pirkka V; Thompson, David M et al. (2013) The association between clinical and radiographic periodontitis measurements during periodontal maintenance. J Periodontol 84:1382-90
Salminen, Aino; Pussinen, Pirkko J; Payne, Jeffrey B et al. (2013) Subantimicrobial-dose doxycycline treatment increases serum cholesterol efflux capacity from macrophages. Inflamm Res 62:711-20
Gu, Ying; Walker, Clay; Ryan, Maria E et al. (2012) Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol 4:
Payne, J B; Stoner, J A; Lee, H-M et al. (2011) Serum bone biomarkers and oral/systemic bone loss in humans. J Dent Res 90:747-51
Payne, Jeffrey B; Golub, Lorne M (2011) Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic. Pharmacol Res 63:121-9
Payne, Jeffrey B; Golub, Lorne M; Stoner, Julie A et al. (2011) The effect of subantimicrobial-dose-doxycycline periodontal therapy on serum biomarkers of systemic inflammation: a randomized, double-masked, placebo-controlled clinical trial. J Am Dent Assoc 142:262-73
Bretz, Walter A (2011) Low-dose doxycycline plus additional therapies may lower systemic inflammation in postmenopausal women with periodontitis. J Evid Based Dent Pract 11:194-5
Gu, Ying; Lee, Hsi-Ming; Simon, Sanford R et al. (2011) Chemically modified tetracycline-3 (CMT-3): a novel inhibitor of the serine proteinase, elastase. Pharmacol Res 64:595-601

Showing the most recent 10 out of 19 publications